Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib

Introduction: Dacomitinib is an epidermal growth factor receptor (EGFR) inhibitor approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in the first line in patients with EGFR activating mutations. Dacomitinib is taken orally once daily at 45 mg with or without food, until dise...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ana Ruiz-Garcia, Weiwei Tan, Jerry Li, May Haughey, Joanna Masters, Jennifer Hibma, Swan Lin
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2020-04-01
Series:	Pharmaceutics
Assuntos:	zero-order absorption first-order absorption combined zero- and first-order absorption transit compartment absorption model
Acceso en liña:	https://www.mdpi.com/1999-4923/12/4/330
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!